Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. more
Time Frame | SLXN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.77% | 0.49% | -0.42% |
1-Month Return | -28.68% | -3.1% | -2.2% |
3-Month Return | 519.41% | -8.59% | 2.38% |
6-Month Return | -84.1% | -4.57% | 5.1% |
1-Year Return | -82.4% | -0.94% | 23.79% |
3-Year Return | -80% | 2.88% | 26.66% |
5-Year Return | -80.6% | 35.84% | 81.16% |
Dec '12 | Dec '22 | Dec '23 | ||||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Cost of Revenue | - | - | - | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Gross Profit | - | - | - | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Gross Margin | - | - | - | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Operating Expenses | - | 3.86M | 4.68M | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":82.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Operating Income | - | (3.86M) | (4.68M) | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-386000000,"profit":false},{"date":"2023-12-31","value":-468100000,"profit":false}] | ||
Total Non-Operating Income/Expense | - | 396.00K | (395.00K) | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-99.75,"profit":false}] | ||
Pre-Tax Income | - | (3.46M) | (5.08M) | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-346400000,"profit":false},{"date":"2023-12-31","value":-507600000,"profit":false}] | ||
Income Taxes | - | - | - | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Income After Taxes | - | - | - | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Income From Continuous Operations | - | (3.49M) | (5.11M) | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-348800000,"profit":false},{"date":"2023-12-31","value":-510800000,"profit":false}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Net Income | - | (3.21M) | (4.94M) | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-321500000,"profit":false},{"date":"2023-12-31","value":-494200000,"profit":false}] | ||
EPS (Diluted) | - | 0.35 | (0.03) | [{"date":"2012-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-7.71,"profit":false}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
SLXN | |
---|---|
Current Ratio | 0.85 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SLXN | |
---|---|
ROA (LTM) | -62.13% |
ROE (LTM) | -116.66% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SLXN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 2.48 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -1.48 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SLXN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.00 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Biomotion Sciences Ordinary Shares (SLXN) share price today is $1.94
Yes, Indians can buy shares of Biomotion Sciences Ordinary Shares (SLXN) on Vested. To buy Biomotion Sciences Ordinary Shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SLXN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Biomotion Sciences Ordinary Shares (SLXN) via the Vested app. You can start investing in Biomotion Sciences Ordinary Shares (SLXN) with a minimum investment of $1.
You can invest in shares of Biomotion Sciences Ordinary Shares (SLXN) via Vested in three simple steps:
The 52-week high price of Biomotion Sciences Ordinary Shares (SLXN) is $13.56. The 52-week low price of Biomotion Sciences Ordinary Shares (SLXN) is $0.21.
The price-to-earnings (P/E) ratio of Biomotion Sciences Ordinary Shares (SLXN) is
The price-to-book (P/B) ratio of Biomotion Sciences Ordinary Shares (SLXN) is 0.00
The dividend yield of Biomotion Sciences Ordinary Shares (SLXN) is 0.00%
The market capitalization of Biomotion Sciences Ordinary Shares (SLXN) is $3.11M
The stock symbol (or ticker) of Biomotion Sciences Ordinary Shares is SLXN